2013 - PhD, Molecular Genetics, Kings College London, UK.
2009 - MSc, Molecular Genetics, Kings College London, UK.
2006 - BA, Human Sciences, University of Oxford, UK.
I am Group Leader of the DNA Methylation Biomarkers group at the Garvan Institute of Medical Research and Conjoint Lecturer at St Vincent's Clinical School, UNSW Sydney. My group's mission is to use epigenetics to improve cancer diagnosis and prognosis, so that patients can receive the correct treatment. We use the latest techniques to study the epigenetic mechanisms underpinning tumour progression, with a particular focus on cells in the tumour microenvironment, and then apply this information to improve interpretation of patient samples.
|Title of Project||Role in Project||Funding Organisation||Start Date||Duration||Total Grant Amount AUD$|
Decoding the epigenome of the tumour microenvironment for improved patient outcomes in prostate cancer
A novel predictive epigenetic test to correctly select men for prostate cancer focal therapy
|CIA||Cancer Council New South Wales||2018||2 years||$300,000|
New opportunities to distinguish low risk from high risk prostate cancer: epigenetic changes in the prostate cancer microenvironment
2015 - Cancer Institute New South Wales Early Career Fellowship
2013 - Gottesmann-Shields Award for the best PhD across SGDP Department, King’s College London, UK
2012 - Tadion Rideal Prize for the best biomedical PhD across King’s College London, UK
2008 - MRC Studentship for MSc/PhD course at King’s College London, UK
Travel awards and prizes for oral and poster presentations at local and international conferences
The research in Ruth's group focuses primarily on the role of epigenetics in the prostate tumour microenvironment. Their goal is to use this epigenetic information to improve cancer diagnosis and prognosis, so that patients can receive the correct treatment.